ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to with your member or guest account, and visit the subscription center available under your account profile.

Showing results for Advocacy

April 17, 2024

Cancer doctors from across the U.S. are lending their voices to a new advocacy campaign to end drug shortages. Led by the Association for Clinical Oncology (ASCO), nearly 500 oncology professionals have signed an open letter to Congress and the administration highlighting the severe impact of drug shortages on cancer care and urging swift action from lawmakers.

April 12, 2024

On April 10, 2024, the Centers for Medicare & Medicaid Services issued the fiscal year (FY) 2025 Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Prospective Payment System (PPS) proposed rule. The rule would update Medicare fee-for-service payment rates and policies for inpatient hospitals and LTCHs for FY 2025. Initial highlights of the proposal are included here.

April 9, 2024

The Centers for Medicare & Medicaid Services released the 2025 Notice of Benefit and Payment Parameters final rule and the 2025 Medicare Advantage and Part D final rule. The Association for Clinical Oncology (ASCO) submitted comments on the proposed versions of both rules. Summaries of the final rules, highlighting provisions ASCO commented on, are included here.  

April 9, 2024

The Association for Clinical Oncology (ASCO) is holding its annual Advocacy Summit Week of Action from April 15-19, during which ASCO members are encouraged to connect with their Members of Congress about policies and legislation that impact cancer care and research. Participants may visit the ACT Network to contact their lawmakers and urge them to take action on priority issues.

April 9, 2024

State governments are increasingly considering legislation to streamline prior authorizations processes, which Association for Clinical Oncology (ASCO) members say delay patient care, adversely affect cancer care outcomes, and divert providers from patient care. States have regulatory authority over fully insured health benefit plans (group and individual plans) and health benefit plans administered by the state itself (Medicaid and state employee benefit plans). This means that state governments can impact plan design through either legislation or regulatory action, and during the past decade, a majority of states have been working to leverage that impact to reform prior authorization.

March 22, 2024

Congress passed a spending package March 23, 2024, that funds the federal government, including the National Institutes of Health (NIH) and National Cancer Institute (NCI), through September 30— the end of the 2024 Fiscal Year.

March 18, 2024

President Biden signed the Consolidated Appropriations Act of 2024, which included a +1.68% adjustment to the Medicare Physician Fee Schedule (MPFS) conversion factor (CF) for the remainder of  calendar year (CY) 2024. This increase results in a 1.68% reduction to the 3.37% CF cut finalized in the 2024 MPFS final Rule. The Association for Clinical Oncology (ASCO) advocated for Congress to address the full 3.37% Medicare physician reimbursement cut, and while ASCO appreciates congressional action, the Association is disappointed that Congress failed to eliminate the entire reimbursement cut.

March 18, 2024

The Association for Clinical Oncology (ASCO) and other health care organizations are recognizing the proposed Health Workforce Well-Being Day of Awareness and calling on Congress to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act.

March 12, 2024

President Biden unveiled his proposed Fiscal Year 2025 federal budget on March 11 that prioritizes cancer research and strengthens the U.S. Department of Health and Human Services’ (HHS) ability to tackle potential disruptions and shortages of vital medicines, including those for cancer.

March 12, 2024

The Association for Clinical Oncology (ASCO) is closely following cases before the United States Supreme Court that have the potential to significantly impact the delivery of cancer care in the U.S. by reshaping the authority of the federal agencies that regulate health care in the country. The Court is expected to issue rulings in these cases before its current session ends in June 2024.

March 11, 2024

In his last State of the Union address this term, President Joe Biden emphasized critical policy priorities that the Association for Clinical Oncology (ASCO) continues to advocate for on behalf of oncologists, their teams, and the profession.

March 11, 2024

Congress passed a six-part spending bill on March 8, 2024, that funds several government agencies, including the Food and Drug Administration (FDA), through Sept. 30, 2024—the end of the fiscal year.

March 7, 2024

The Association for Clinical Oncology (ASCO) is urging President Biden to keep cancer care and research among his top national priorities on the eve of his State of the Union Address.

February 29, 2024

Congress passed a continuing resolution (CR) on February 29, 2024, that extends FY 2023 federal funding levels until March 22 for several government agencies, including the National Institutes of Health (NIH) and the National Cancer Institute (NCI).

February 28, 2024

The President's Cancer Panel published a report on February 28 on the National Cancer Plan that includes mention of seven American Society of Clinical Oncology (ASCO) programs that are contributing to the plan.